Korean Biotech Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Feed
13:30
Sep 09
Sep 09
Add KOSDAQ biotech; rebound must participate.
Shin argues that if KOSDAQ is going to rise, biotech must participate, so even though he had reduced his biotech weighting, he thought from today it was time to start adding back. Biotech is one of the core KOSDAQ growth sectors that led the rebound and can continue in rotation.
MED
12:30
Sep 04
Sep 04
Korean biotech bottoming on rate catalysts.
Korean biotech sentiment has already deteriorated about as much as it can with rates near a peak, so the sector has limited room for further sentiment damage. Licensing-out news or lower and more stable rates could quickly trigger moves in many biotech names.
MED
02:03
Sep 01
Sep 01
Four sectors where earnings and narrative align
Prefers a concentrated four-sector portfolio of semiconductors, electric electronics, power equipment, and biotech because those are the sectors where earnings and narrative, the two engines that move stock prices, currently align. His disclosed allocation was 31% semiconductors, 17% power equipment, 13% electric electronics, 15% biotech, and 20% cash.
HIGH
07:33
Aug 25
Aug 25
Balance AI and non-AI Korean sectors.
Investors should not chase only Samsung Electronics and SK Hynix in AI; balance AI exposure such as Samsung Electronics, SK Hynix, semiconductor materials/parts/equipment, and power equipment against non-AI sectors like cosmetics, biotech, and secondary batteries, while keeping 20-40% cash to deploy on sharp dips.
MED
04:31
Aug 24
Aug 24
KOSDAQ growth stocks are unfairly lagging US peers.
While US growth stocks like ARK Invest and biotech ETFs are hitting new highs despite rate concerns, KOSDAQ growth and biotech stocks are unfairly suppressed by local supply-demand dynamics, presenting a potential catch-up opportunity.
MED
08:00
Aug 23
Aug 23
Korean cosmetics, biotech, shipbuilding are growing.
Beyond semiconductors, Korean export data shows cosmetics and biotech have been steadily improving since last year, and shipbuilding orders have recently been good; they are too small to fully replace semiconductors if semis rest, but they are real secondary candidates.
MED
08:10
Aug 21
Aug 21
Avoid biotechs rallying purely on Moderna sympathy.
Korean biotech stocks that rallied purely in sympathy with Moderna's recent surge, without any fundamental business connection or hard data of their own, are vulnerable to sharp corrections. Moderna's own stock experienced a 20% pullback after its massive run, and Korean peers lacking solid catalysts will likely face similar profit-taking.
MED
03:16
Aug 20
Aug 20
Buy Korean biotech targeting US tech exports.
Korean biotech stocks are attractive now, specifically those expected to license out technology to US Big Pharma in the obesity and oncology sectors. While the sector lacks broad momentum, individual companies with tangible export achievements will see strong investor sentiment improvement.
MED
23:00
Aug 19
Aug 19
Buy biotech firms with tech export potential.
Rather than buying the broad biotech sector dominated by large caps, investors should pick individual Korean biotech companies with strong potential to export technology to US Big Pharma, particularly in the obesity and oncology fields, and hold them for expected second-half results.
MED
11:03
Aug 19
Aug 19
Buy biotech in summer for winter catalysts.
Korean biotech stocks exhibit strong seasonality: buy in summer and sell in winter. Major catalysts and clinical results from global conferences typically emerge from September through winter, making the sector attractive to accumulate now.
MED
08:46
Aug 19
Aug 19
Buy biotech in summer for winter catalysts.
Korean biotech stocks exhibit strong seasonality. Investors should buy in the summer and sell in the winter, as major clinical catalysts and licensing events typically occur from September through early next year.
HIGH
04:00
Aug 13
Aug 13
KOSDAQ bio/robotics rotation likely now.
With rate-hike concerns easing and no earnings announcements near term, the non-earnings/macro-focused period favors KOSDAQ small/mid-cap strategies, especially biotech and robotics. KOSDAQ has already risen 38% from the bottom, but holding its trend without breaking down is enough for now.
MED
03:16
Aug 11
Aug 11
Korean biotech will follow US biotech highs.
US biotech stocks are hitting new historical highs, and Korean biotech stocks are likely to follow this upward trend with a time lag.
MED
00:31
Jun 30
Jun 30
Rotate from semis to biotech, cosmetics, entertainment
Second half of the year will see a broader market rally beyond semiconductors. Allocation should shift from an overweight in semiconductors (70% of equity bucket) to a more balanced 50/50 split, adding exposure to Korean biotech, cosmetics, and entertainment sectors. The rotation is driven by semiconductor rebalancing flows, government mega projects that highlight power and infrastructure, and physical AI trends that benefit robotics.
HIGH
08:27
Jun 24
Jun 24
Avoid new Korean biotech positions.
Korean biotech's rally today is not driven by fundamentals but merely a catch-up to the US biotech index which hit all-time highs. Korean biotech is structurally cyclical and sensitive to interest rates, unlike defensive US biotech. The sector lacks sustainable earnings momentum. New buying is risky; existing holders should use the bounce to reduce positions.
MED
11:00
May 20
May 20
Avoid Korean biotech for now.
The Korean biotech sector currently lacks new buying interest and has lost its appeal. Despite claims of no issues, stocks continue to fall with low volume, indicating no catalyst for a rebound. Avoid until fresh money flows in.
MED
11:00
May 18
May 18
Avoid Korean biotech sector.
The biotech sector lacks fundamental support and positive sentiment; even good news leads to profit-taking. The bottom is not confirmed, so investors should avoid trying to catch the bottom.
MED
03:00
May 13
May 13
Korean biotech sector rotation play
Korean biotech stocks are poised to rally after the Q1 earnings season ends, as money rotates from semiconductors into 'dream stocks' like biotech and robotics for May-June. Alteogen and LigaChem are examples that have already moved.
LOW
About Korean Biotech Investor Commentary
Across the available history and selected sources, Buzzberg tracks Korean Biotech across 2 sources: 13 bullish vs 0 bearish calls from 11 authors. Historical directional balance: 72% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 18 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: Shin Hyeok-seung, Hwang Yoo-hyun, Lee Jae-chan.